ALLERGIC RHINITIS TREATMENT MARKET ANALYSIS

Allergic Rhinitis Treatment Market, By Treatment Type (Immunotherapy (Sub-cutaneous Immunotherapy, Sub-lingual Immunotherapy), Anti-histamines, Decongestants, Leukotriene Receptor Antagonists, Corticosteroids, and Others), By Route of Administration (Oral, Nasal, Intraocular, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-commerce), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Apr 2024
Code : CMI1201
Pages :181
Formats :
Excel and PDF
Industry : Pharmaceutical

Key Developments

In May 2023, Altamira Therapeutics Ltd., a global healthcare company, announced positive top-line results from the randomized controlled NASAR clinical trial evaluating its Bentrio nasal spray in patients with seasonal allergic rhinitis (SAR). Bentrio nasal spray is formulated as a drug-free and preservative-free gel emulsion designed to help protect against airborne allergens such as pollen or house dust mites.
In August 2022, Hikma Pharmaceuticals PLC, a pharmaceutical company, announced the launch of RYALTRIS (olopatadine hydrochloride and mometasone furoate nasal spray) in the US. RYALTRIS is approved by the US Food and Drug Administration (FDA) for the treatment of symptoms of seasonal allergic rhinitis (SAR) in adult and pediatric patients 12 years of age and older
In June 2021, through a procedure known as a partial prescription to non-prescription transition, the U.S. Food and Drug Administration (FDA) approved a nasal antihistamine for non-prescription use. The US FDA approved Astepro (azelastine hydrochloride nasal spray, 0.15%) for seasonal and perennial allergic rhinitis, commonly known as allergies for adults and children six years of age and older
In November 2021, Revolo Biotherapeutics, a biotherapeutics company, started a phase II clinical trial for IRL201104, a novel immunomodulatory peptide drug indicated for seasonal allergic rhinitis.
In March 2021, ALK-Abelló A/S, a pharmaceutical company, announced its submission of a registration application in China, under National Medical Products Administration (NMPA), Chinese agency for regulating drugs and medical devices, for its ACARIZAX, a house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet